A 2-(furan-2-ylmethylene)-4-nitrobutyrate compound and its preparation method and application
The method for preparing 2-(furan-2-ylmethylene)-4-nitrobutyrate compounds solves the problems of high cost and harsh reaction conditions in the synthesis of benzofuran-6-carboxylic acid in the prior art, and realizes low-cost and convenient industrial production.
Patent Information
- Application Number
- CN202310503625.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-06
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-05-06
AI Technical Summary
Existing methods for synthesizing benzofuran-6-carboxylic acid are costly, have difficult-to-obtain raw materials, and require harsh reaction conditions, making industrial-scale production difficult.
Benzofuran-6-carboxylic acid was prepared by reacting 2-(furan-2-ylmethylene)-4-nitrobutyrate as an intermediate with furfural, Boc anhydride and nitromethane. All reactions were carried out under conventional conditions, avoiding ultra-low and ultra-high temperatures.
The synthesis cost has been reduced and the process has been simplified, making the preparation of benzofuran-6-carboxylic acid more convenient and suitable for industrial production.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic synthesis, and specifically relates to a 2-(furan-2-ylmethylene)-4-nitrobutyrate compound and a preparation method and application thereof. Background Art
[0002] The chemical structure of Lifitegrast consists of three parts: A, B, and C. The chemical structure of Lifitegrast is shown below:
[0003]
[0004] Usually, the structure corresponding to fragment A is benzofuran-6-carboxylic acid (compound F), and the chemical structure of benzofuran-6-carboxylic acid is shown below:
[0005]
[0006] WO2014018748A1 discloses the steps of preparing Lipfest from benzofuran-6-carboxylic acid.
[0007] WO2014018748A1, page 35, discloses a method for synthesizing benzofuran-6-carboxylic acid, and the reaction formula is as follows:
[0008]
[0009] This method has the following disadvantages: (1) The production process of the starting material 2-(2-bromoethyl)-1,3-dioxolane is special, there are very few manufacturers, and the price fluctuates greatly; (2) The first step needs to be carried out under high temperature conditions of 160°C, which is a reaction device that requires an independent heating system and is not suitable for general intensive heating factory production mode; (3) The second step requires LDA, which is expensive and needs to be carried out at ultra-low temperatures, and the overall implementation cost is very high; (4) Although the LDA used in the second step can also be replaced by other types of metal reagents, such as butyl lithium, NaHMDS, and LiHMDS, they are also expensive and also need to be carried out at ultra-low temperatures, and the implementation cost is very high.
[0010] The document ACS Medicinal Chemistry Letters (2012), 3(3), 203-206 discloses in detail a method for synthesizing benzofuran-6-carboxylic acid (as shown in the following reaction formula):
[0011]
[0012] This method has the following disadvantages: (1) the raw materials of the first step, 6-hydroxy-2H-benzofuran-3-one and tert-butyldimethylchlorosilane, and the raw materials of the third step, N-phenylbis(trifluoromethanesulfonyl)imide and palladium acetate, are all expensive; (2) the third step requires carbon monoxide, which is a toxic gas, and the reaction conditions need to be carried out under heating and high pressure conditions, which is difficult to implement. Combined with the above two points, the total cost of this route is very high and has no commercial value.
[0013] Therefore, how to provide an intermediate compound that can be used to more conveniently synthesize benzofuran-6-carboxylic acid has become a problem that needs to be solved urgently. Summary of the invention
[0014] In view of the shortcomings of the prior art, the object of the present invention is to provide a 2-(furan-2-ylmethylene)-4-nitrobutyrate compound and its preparation method and application. The 2-(furan-2-ylmethylene)-4-nitrobutyrate compound provided by the present invention makes the step of preparing the intermediate benzofuran-6-carboxylic acid of the dry eye drug Lifitegrast more convenient.
[0015] To achieve this object, the present invention adopts the following technical solutions:
[0016] In a first aspect, the present invention provides a 2-(furan-2-ylmethylene)-4-nitrobutyrate compound, wherein the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound has a structure as shown in the following formula I:
[0017]
[0018] Among them, R1 is selected from C1-C6 (for example, it can be C1, C2, C3, C4, C5, C6, etc.) straight chain alkyl or C1-C6 (for example, it can be C1, C2, C3, C4, C5, C6, etc.) branched chain alkyl.
[0019] In a second aspect, the present invention provides a method for preparing the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound according to the first aspect, the preparation method comprising the following steps:
[0020] (1) reacting the compound represented by formula II with furfural in the presence of a catalyst to generate the compound represented by formula III, as shown in the following reaction formula:
[0021]
[0022] (2) reacting the compound represented by formula III with Boc anhydride in the presence of a catalyst to generate a compound represented by formula IV. The reaction formula is as follows:
[0023]
[0024] (3) reacting the compound represented by formula IV with nitromethane in the presence of a base to generate the compound represented by formula I. The reaction formula is as follows:
[0025]
[0026] Wherein, R1 in the structural formula of each of the above steps is selected from C1-C6 straight chain alkyl or C1-C6 branched chain alkyl.
[0027] In the present invention, in step (1), the molar ratio of the compound represented by formula II to furfural is (1-4):1 (wherein, "1-4" can be 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3, 3.2, 3.4, 3.6, 3.8, 4, etc.).
[0028] Preferably, in step (1), the molar ratio of the catalyst to furfural is (0.5-1.8):1 (wherein, "0.5-1.8" can be 0.5, 0.7, 0.9, 1.1, 1.3, 1.5, 1.7, 1.8, etc.).
[0029] Preferably, in step (1), the catalyst comprises a tertiary amine and / or a trialkyl phosphine.
[0030] Preferably, the tertiary amine includes any one or a combination of at least two of DABCO, a quinoline ring or a structure shown in the following formula V:
[0031]
[0032] Among them, R a , R b Each is independently selected from any one of hydrogen, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, substituted or unsubstituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) alkylaryl, and substituted or unsubstituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12) arylcarbonyl;
[0033] R c Any one selected from hydrogen, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy or halogen; n is selected from an integer between 1 and 5 (for example, 1, 2, 3, 4, 5, etc.).
[0034] Preferably, in step (1), the catalyst is DABCO (triethylenediamine).
[0035] Preferably, the trialkylphosphine includes any one of triethylphosphine, tributylphosphine, tricyclohexylphosphine or triphenylphosphine.
[0036] In the present invention, in step (1), the reaction is carried out in the presence of a solvent, and the solvent includes an aprotic solvent.
[0037] Preferably, the aprotic solvent includes any one of dichloromethane, chloroform, methyl tert-butyl ether, 1,2-dichloroethane, ethyl acetate, toluene, petroleum ether, n-hexane, n-heptane, acetonitrile, ethylene glycol dimethyl ether, N,N-dimethylformamide or dimethyl sulfoxide, or a combination of at least two thereof.
[0038] Preferably, in step (1), the reaction temperature is 10-30°C (for example, it can be 10°C, 12°C, 14°C, 16°C, 18°C, 20°C, 22°C, 24°C, 26°C, 28°C, 30°C), and the reaction time is 40-60h (for example, it can be 40h, 42h, 44h, 46h, 48h, 50h, 52h, 54h, 56h, 58h, 60h, etc.).
[0039] In the present invention, in step (2), the molar ratio of the compound represented by formula III to Boc anhydride is (0.8-1.2):1 (wherein, "0.8-1.2" can be 0.8, 0.9, 1, 1.1, 1.1, 1.2, etc.).
[0040] Preferably, in step (2), the molar ratio of the compound represented by formula III to the catalyst is (8-20):1 (wherein, "8-20" can be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.).
[0041] Preferably, in step (2), the catalyst comprises DMAP or any one of the compounds represented by the following formula VI:
[0042]
[0043] Among them, R d Any one selected from hydrogen, amino, nitro, hydroxyl, halogen, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy, and m is selected from an integer between 1 and 5 (for example, 1, 2, 3, 4, 5, etc.).
[0044] In the present invention, in step (2), the reaction is carried out in the presence of a solvent, and the solvent includes an aprotic solvent.
[0045] Preferably, the aprotic solvent includes any one of dichloromethane, chloroform, methyl tert-butyl ether, 1,2-dichloroethane, ethyl acetate, toluene, petroleum ether, n-hexane, n-heptane, acetonitrile, ethylene glycol dimethyl ether, N,N-dimethylformamide or dimethyl sulfoxide, or a combination of at least two thereof.
[0046] Preferably, in step (2), the reaction temperature is 0-30°C (for example, it can be 0°C, 3°C, 6°C, 8°C, 12°C, 15°C, 18°C, 21°C, 24°C, 27°C, 30°C, etc.), and the reaction time is 6-15h (for example, it can be 6h, 7h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, etc.).
[0047] In the present invention, in step (3), the molar ratio of the compound represented by formula IV to nitromethane is 1:(4-6) (wherein, "4-6" can be 4, 4.2, 4.4, 4.6, 4.8, 5, 5.2, 5.4, 5.6, 5.8, 6, etc.).
[0048] Preferably, in step (3), the molar ratio of the compound represented by formula IV to the base is (8-12):1 (wherein, "8-12" can be 8, 9, 10, 11, 12, etc.).
[0049] Preferably, in step (3), the base comprises any one or a combination of at least two of cesium carbonate, sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydroxide, lithium hydroxide or potassium hydroxide.
[0050] In the present invention, in step (3), the reaction is carried out in the presence of a solvent, and the solvent includes an aprotic solvent.
[0051] Preferably, the aprotic solvent includes any one of 1,4-dioxane, dichloromethane, chloroform, methyl tert-butyl ether, 1,2-dichloroethane, toluene, petroleum ether, n-hexane, n-heptane or ethylene glycol dimethyl ether, or a combination of at least two thereof.
[0052] Preferably, in step (3), the reaction temperature is 40-60°C (for example, it can be 40°C, 42°C, 44°C, 46°C, 48°C, 50°C, 52°C, 54°C, 56°C, 58°C, 60°C, etc.), and the reaction time is 6-15h (for example, it can be 6h, 7h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, etc.).
[0053] In a third aspect, the present invention provides a use of the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound according to the first aspect in the preparation of Lifest, a drug for treating dry eye disease.
[0054] In a fourth aspect, the present invention provides a use of the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound according to the first aspect in the preparation of benzofuran-6-carboxylic acid, an intermediate of the drug Lifest for treating dry eye disease.
[0055] In the present invention, the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound is first prepared to obtain a 2-(furan-2-ylmethylene)-4,4-dialkoxybutyrate compound, and then to obtain a benzofuran-6-carboxylic acid.
[0056] Preferably, the structure of the 2-(furan-2-ylmethylene)-4,4-dialkoxybutyrate compound is as shown in formula a-1:
[0057]
[0058] In the formula, R1 has the same definition as above, and R2 is selected from a C1-C6 straight chain alkyl group or a C1-C6 branched chain alkyl group.
[0059] In the present invention, the preparation method of benzofuran-6-carboxylic acid comprises the following steps:
[0060] (1) reacting the compound represented by formula I and a base in an alcohol solvent to obtain a mixture;
[0061] The alcohol solvent is selected from C1-C6 straight-chain alkyl alcohol or C1-C6 branched alkyl alcohol; the molar ratio of the compound represented by formula I to the base is 1:(1.5-2.5); the base includes an organic base and / or an inorganic base; the organic base includes any one of sodium methoxide, sodium ethoxide, sodium tert-butoxide or potassium tert-butoxide or a combination of at least two; the inorganic base includes any one of lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydride, sodium hydride or potassium hydride or a combination of at least two; the reaction temperature is -5 to 5°C, and the reaction time is 20-90 min;
[0062] (2) reacting the mixture obtained in step (1) with an acid in an alcohol solvent to obtain a compound represented by formula a-1. The reaction formulas of step (1) and step (2) are as follows:
[0063]
[0064] The alcohol solvent is selected from C1-C6 straight-chain alkyl alcohol or C1-C6 branched alkyl alcohol; the molar ratio of the compound represented by formula I to the acid is 1:(2-8); the acid includes any one of hydrochloric acid, sulfuric acid, phosphoric acid or polyphosphoric acid or a combination of at least two; the reaction temperature is -5 to 5°C, and the reaction time is 20-90 min; R2 and R2 exist independently or are connected to form a ring;
[0065] (3) reacting the compound represented by formula a-1 in the presence of an acid catalyst to generate the compound represented by formula a-2. The reaction formula is as follows:
[0066]
[0067] The molar ratio of the compound represented by formula a-1 to the acid catalyst is 1:(5-25); the acid catalyst includes a protonic acid and / or a metal ion Lewis acid; the metal ion Lewis acid includes any one of trihaloaluminum, ferric chloride or zinc chloride or a combination of at least two thereof; the trihaloaluminum includes aluminum trichloride; the protonic acid includes any one of phosphoric acid, sulfuric acid or polyphosphoric acid or a combination of at least two thereof; the reaction temperature is 20-100°C, and the reaction time is 12-48h;
[0068] (4) The compound represented by formula a-2 obtained in step (3) is hydrolyzed under alkaline conditions to obtain benzofuran-6-carboxylic acid. The reaction formula is as follows:
[0069]
[0070] Compared with the prior art, the present invention has the following beneficial effects:
[0071] In the preparation process of the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound provided by the present invention, all materials are cheap and readily available, and all reaction steps adopt conventional reaction conditions without involving ultra-low temperature and ultra-high temperature. In addition, the synthesis cost is low and it is easy to industrialize production. The 2-(furan-2-ylmethylene)-4-nitrobutyrate compound provided by the present invention makes the step of preparing benzofuran-6-carboxylic acid, an intermediate of Lipfest, a drug for treating dry eye disease, more convenient. DETAILED DESCRIPTION
[0072] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only used to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0073] In the following embodiments and application examples, the room temperature was 25° C. and the overnight reaction time was 16 h.
[0074] Example 1
[0075] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), and the preparation method of the 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1) comprises the following steps:
[0076]
[0077] (1) Methyl acrylate (2.58 g, 30 mmol) was added to furfural (0.96 g, 10 mmol) and dichloromethane (20 mL), and DABCO (triethylenediamine) as a catalyst (1.12 g, 10 mmol) was added under stirring. The mixture was stirred at room temperature for 48 hours. When the furfural raw material disappeared after the plate detection, 10 mL of ethyl acetate and dilute hydrochloric acid (1 N, 10 mL) were added. The mixture was stirred, separated, dried, and spin-dried to obtain 1.6 g of compound A1 with a yield of 88%;
[0078] Structure identification: MS (ESI+): 183.2;
[0079] 1 H NMR(400MHz, CDCl3), δ3.12(s,1H),3.82(s,3H),5.64(s,1H),6.00(s,1H),6. 31 (d, J = 3.2 Hz, 1H), 6.39 (q, J = 1.6 Hz, 1H), 6.44 (s, 1H), 7.43 (q, J = 0.8 Hz, 1H).
[0080] (2) Dissolve compound A1 (7.06 g, 38.75 mmol) in 49 ml of dichloromethane, stir, add catalyst DMAP (0.47 g, 3.87 mmol), and add Boc anhydride (8.87 g, 40.69 mmol) dropwise in an ice-water bath. After the addition is complete, naturally warm to room temperature and stir overnight. Add 25 ml of water, stir, separate the liquids, dry, and concentrate through a column to obtain 8.97 g of compound B1, with a yield of 82%;
[0081] Structure identification: MS (ESI+): 227.3;
[0082] 1 H NMR (400MHz, CDCl3), δ1.52 (s, 9H), 3.79 (s, 3H), 6.10 (s, 1H), 6.35-6.39 (m, 2H), 6.53 (s, 1H), 6.60 (s, 1H), 7.43 (q, J = 0.8Hz, 1H).
[0083] (3) Compound B1 (2.82 g, 10 mmol) was dissolved in 5 ml of 1,4-dioxane, and nitromethane (3.05 g, 50 mmol) and cesium carbonate (0.326 g, 1 mmol) were added under stirring, and the temperature was raised to 50°C and stirred overnight. The solvent was removed by spinning, and the mixture was filtered through a column to obtain 1.67 g of compound C1, with a yield of 74%;
[0084] Structure identification: MS (ESI+): 226.3;
[0085] 1 H NMR(400MHz, CDCl3), δ3.54(t,J=8.0Hz,2H),3.87(s,3H),4.60(t,J=8.0Hz,2H), 6.58(q,J=1.6Hz,1H), 6.76(d,J=3.2Hz,1H), 7.57(s,1H), 7.63(q,J=0.8Hz,1H).
[0086] Example 2
[0087] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid ethyl ester compound (C2), and the preparation method of the 2-(furan-2-ylmethylene)-4-nitrobutyric acid ethyl ester compound (C2) comprises the following steps:
[0088]
[0089] (1) Ethyl acrylate (3 g, 30 mmol) was added to furfural (0.77 g, 8 mmol) and chloroform (18 mL), and quinoline ring was added as a catalyst (1.33 g, 12 mmol) under stirring. The mixture was stirred at room temperature for 50 hours. When the furfural raw material disappeared after the plate detection, 10 mL of ethyl acetate and dilute hydrochloric acid (1N, 10 mL) were added. The mixture was stirred, separated, dried, and spin-dried to obtain 1.26 g of compound A2 with a yield of 80%;
[0090] Structure identification: MS (ESI+): 197.1;
[0091] 1 H NMR(400MHz, CDCl3), δ1.31(t,J=7.2Hz,3H),3.21(s,1H),4.27(qd,J1=7.2Hz,J2=0.4Hz,2H),5.62( s,1H),5.96(s,1H),6.30(d,J=0.8Hz,1H),6.37(q,J=1.6Hz,1H),6.42(s,1H),7.41(q,J=0.8Hz,1H).
[0092] (2) Dissolve compound A2 (6.86 g, 35 mmol) in 45 ml of chloroform, stir, add catalyst pyridine (0.25 g, 3.2 mmol), and add Boc anhydride (8.4 g, 38.5 mmol) dropwise in an ice-water bath. After the addition is complete, naturally warm to room temperature and stir overnight. Add 25 ml of water, stir, separate the liquids, dry, and concentrate through a column to obtain 7.9 g of compound B2, with a yield of 76%;
[0093] Structure identification: MS (ESI+): 241.2;
[0094] 1 H NMR (400MHz, CDCl3), δ1.41 (t, J=7.2Hz, 3H), 1.58 (s, 9H), 4.38 (qd, J1=7.2Hz, J2=0.4Hz, 2H), 5. 33-5.36(m,2H),6.55(q,J=1.6Hz,1H),6.64(d,J=3.2Hz,1H),7.65(d,J=1.6Hz,1H),7.68(s,1H).
[0095] (3) Compound B2 (2.96 g, 10 mmol) was dissolved in 5.5 ml of dichloromethane, and nitromethane (3.17 g, 52 mmol) and sodium carbonate (0.12 g, 1.1 mmol) were added under stirring, and the temperature was raised to 55°C and stirred overnight. The solvent was removed by spinning, and the mixture was filtered through a column to obtain 1.9 g of compound C2, with a yield of 80%;
[0096] Structure identification: MS (ESI+): 240.2;
[0097] 1 H NMR(400MHz, CDCl3), δ1.38(t,J=7.2Hz,3H),3.54(t,J=8.0Hz,2H),4.32(q,J=7.2Hz,2H),4.60( t,J=8.0Hz,2H),6.57(q,J=1.6Hz,1H),6.75(d,J=3.2Hz,1H),7.56(s,1H),7.64(q,J=0.8Hz,1H).
[0098] Example 3
[0099] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid isopropyl ester compound (C3), and the preparation method of the 2-(furan-2-ylmethylene)-4-nitrobutyric acid isopropyl ester compound (C3) comprises the following steps:
[0100]
[0101] (1) Isopropyl acrylate (3.4 g, 30 mmol) was added to furfural (1.15 g, 12 mmol) and methyl tert-butyl ether (22 mL), and tributylphosphine (1.82 g, 9 mmol) was added as a catalyst under stirring. The mixture was stirred at room temperature for 46 hours. The furfural raw material disappeared after spot plate detection. 10 mL of ethyl acetate and dilute hydrochloric acid (1N, 10 mL) were added, stirred, separated, dried, and spin-dried to obtain 1.85 g of compound A3, with a yield of 88%;
[0102] Structure identification: MS (ESI+): 211.2;
[0103] 1 H NMR(400MHz, CDCl3), δ1.27(d,J=6.4Hz,3H),1.29(d,J=6.4Hz,3H),3.20(s,1H),5.12(septet,J=6.4Hz,1H) ,5.61(s,1H),5.93(s,1H),6.30(d,J=3.2Hz,1H),6.38(q,J=1.6Hz,1H),6.40(s,1H),7.42(q,J=0.8Hz,1H).
[0104] (2) Dissolve compound A3 (7.84 g, 35 mmol) in 55 ml of methyl tert-butyl ether, stir, add catalyst 2-methylpyridine (0.33 g, 3.5 mmol), and add Boc anhydride (9.16 g, 42 mmol) dropwise in an ice-water bath. After the addition is complete, naturally warm to room temperature and stir overnight. Add 25 ml of water, stir and separate, dry, and concentrate through a column to obtain 10.3 g of compound B3, with a yield of 95%;
[0105] Structure identification: MS (ESI+): 255.2;
[0106] 1 H NMR (400MHz, CDCl3), δ1.34 (d, J=6.4Hz, 6H), 1.54 (s, 9H), 5.12-5.22 (septet, J=6.4Hz, 1H), 5.30(s,2H),6.55(q,J=1.6Hz,1H),6.78(d,J=3.2Hz,1H),7.60(d,J=1.6Hz,1H),7.62(s,1H).
[0107] (3) Compound B3 (3.24 g, 10 mmol) was dissolved in 5 ml of 1,2-dichloroethane, and nitromethane (2.93 g, 48 mmol) and cesium carbonate (0.293 g, 0.9 mmol) were added under stirring, and the temperature was raised to 45°C and stirred overnight. The solvent was removed by spinning, and the mixture was filtered through a column to obtain 1.93 g of compound C3, with a yield of 76%;
[0108] Structure identification: MS (ESI+): 254.2;
[0109] 1 H NMR(400MHz, CDCl3), δ1.37(d,J=6.4Hz,6H),3.54(t,J=8.0Hz,2H),4.60(t,J=8.0Hz,2H),5.13-5.21( septet,J=6.4Hz,1H),6.58(q,J=1.6Hz,1H),6.75(d,J=3.2Hz,1H),7.54(s,1H),7.63(q,J=0.8Hz,1H).
[0110] Example 4
[0111] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (1), the catalyst DABCO is replaced by an equal molar amount of cinchona alkaloids, and the other preparation methods are the same as those in Example 1.
[0112] Example 5
[0113] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (1), the reaction temperature is increased to 45°C and the reaction time is still 48 hours. The other preparation methods are the same as Example 1.
[0114] Example 6
[0115] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (1), the molar amount of the catalyst DABCO is increased to 20 mmol, and the other preparation methods are the same as Example 1.
[0116] Example 7
[0117] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (1), the molar amount of the catalyst DABCO is reduced to 4.5 mmol, and the other preparation methods are the same as Example 1.
[0118] Example 8
[0119] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (1), the solvent is replaced with n-hexane, and the other preparation methods are the same as Example 1.
[0120] Example 9
[0121] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (1), the molar amount of methyl acrylate is increased to 42 mmol, and the other preparation methods are the same as Example 1.
[0122] Example 10
[0123] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (1), the molar amount of methyl acrylate is reduced to 10 mmol, and the other preparation methods are the same as Example 1.
[0124] Embodiment 11
[0125] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (3), the reaction temperature is increased to 70°C and the reaction time remains unchanged. Other preparation methods are the same as Example 1.
[0126] Example 12
[0127] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (3), the reaction temperature is reduced to 35°C and the reaction time is increased to 20h. The other preparation methods are the same as Example 1.
[0128] Example 13
[0129] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (3), the solvent is replaced with ethylene glycol dimethyl ether, and the other preparation methods are the same as Example 1.
[0130] Embodiment 14
[0131] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (3), the molar amount of nitromethane is reduced to 35 mmol, and the other preparation methods are the same as Example 1.
[0132] Embodiment 15
[0133] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (3), the molar amount of nitromethane is increased to 65 mmol, and the other preparation methods are the same as Example 1.
[0134] Example 16
[0135] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (3), the molar amount of cesium carbonate is increased to 1.4 mmol, and the other preparation methods are the same as Example 1.
[0136] Embodiment 17
[0137] This embodiment provides a 2-(furan-2-ylmethylene)-4-nitrobutyric acid methyl ester compound (C1), which is different from Example 1 only in that in step (3), the molar amount of cesium carbonate is reduced to 0.8 mmol, and the other preparation methods are the same as Example 1.
[0138] Application Example 1
[0139] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0140]
[0141] (1) Compound C1 (22.5 g, 0.1 mol) was dissolved in methanol (11 mL), placed in a dropping funnel, and slowly added dropwise to a mixture of sodium methoxide (11.2 g, 0.2 mol) and methanol (50 mL) at 0°C, and stirred for 30 minutes to obtain a mixed solution. The mixed solution was then placed in a dropping funnel, and slowly added dropwise to a pre-prepared sulfuric acid methanol solution (concentrated sulfuric acid (29.4 g, 0.3 mol) + methanol (150 mL)) at 0°C, and stirred for 30 minutes. After the reaction was completed, 200 mL of dichloromethane and 400 mL of water were added in sequence, stirred thoroughly, and separated. The aqueous phase was extracted once with dichloromethane (100 mL). The organic phases were combined, washed once with saturated NaHCO3, dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-4,4-dimethoxybutyric acid methyl ester compound D1 (10.8 g, yield 45%).
[0142] Structure identification: MS (ESI+) 241.1;
[0143] 1 H NMR(400MHz, CDCl3), δ3.15(d,J=5.6Hz,2H),3.39(s,6H),3.84(s,3H),4.67(t,J=5.6Hz,1H), 6.52(q,J=1.6Hz,1H),6.76(d,J=3.2Hz,1H),7.34(d,J=4.0Hz,1H),7.52(s,1H),7.58(s,1H).
[0144] (2) Compound D1 (24 g, 0.1 mol) was dissolved in methanol (24 mL), and phosphoric acid (85 wt%, 92.2 g, 0.8 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 24 h, and 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid methyl ester compound E1 (16 g, 91%);
[0145] Structure identification: MS (ESI+) 177.1;
[0146] 1 H NMR (400MHz, CDCl3), δ3.99 (s, 3H), 6.86 (dd, J1=2.0Hz, J2=1.0Hz, 1H), 7.67 (d, J= 8.0Hz, 1H), 7.80 (d, J = 2.0Hz, 1H), 8.00 (dd, J1 = 8.0Hz, J2 = 1.4Hz, 1H), 8.25 (s, 1H).
[0147] Subsequently, compound E1 (17.6 g, 0.1 mol) was dissolved in methanol, and sodium hydroxide (8 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0148] Structure identification: MS (ESI-): 161.3;
[0149] 1 H NMR (400MHz, CDCl3), δ6.86 (dd, J1 = 1.6Hz, J2 = 0.8Hz, 1H), 7.67 (d, J = 6.4Hz, 1H), 7.80 (d, J = 2.0Hz, 1H), 8.00 (dd, J1 = 8.4Hz, J2 = 0.8Hz, 1H), 8.30 (s, 1H).
[0150] Application Example 2
[0151] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0152]
[0153] (1) Compound C1 (22.5 g, 0.1 mol) was dissolved in ethanol (20 mL), placed in a dropping funnel, and slowly added dropwise to a mixture of sodium ethoxide (13.6 g, 0.2 mol) and ethanol (50 mL) at 0°C, and stirred for 30 minutes to obtain a mixed solution. The mixed solution was then placed in a dropping funnel, and slowly added dropwise to a pre-prepared sulfuric acid ethanol solution (concentrated sulfuric acid (29.4 g, 0.3 mol) + ethanol (150 mL)) at 0°C, and stirred for 30 minutes. After the reaction was completed, 200 mL of dichloromethane and 400 mL of water were added in sequence, stirred thoroughly, and separated. The aqueous phase was extracted once with dichloromethane (100 mL). The organic phases were combined, washed once with saturated NaHCO3, dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-4,4-diethoxybutyric acid methyl ester compound D1a (11.8 g, yield 44%).
[0154] Structure identification: MS (ESI+) 269.4;
[0155] 1 H NMR(400MHz, CDCl3), δ1.17(t,J=7.2Hz,6H),3.13(d,J=6.0Hz,2H),3.51(q,J=7.2Hz,2H),3.71(q,J=7.2Hz,2H) ,3.81(s,3H),4.74(t,6.0Hz,1H),6.50(q,J=1.6Hz,1H),6.79(d,3.2Hz,1H),7.50(s,1H),7.55(d,J=1.6Hz,1H).
[0156] (2) Compound D1a (26.8 g, 0.1 mol) was dissolved in methanol (24 mL), and phosphoric acid (85 wt%, 92.2 g, 0.8 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 24 h, and 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid methyl ester compound E1 (13 g, 74%);
[0157] Subsequently, compound E1 (17.6 g, 0.1 mol) was dissolved in methanol, and sodium hydroxide (8 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0158] Application Example 3
[0159] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0160]
[0161] (1) Add ethylene glycol (80 mL), add sodium hydride (8 g, 0.2 mol, 60% mineral oil dispersion) in batches under an ice-water bath, control the temperature at 0-10°C, and add it over 30 minutes. Dissolve compound C1 (22.5 g, 0.1 mol) in ethylene glycol (20 mL), place in a dropping funnel, slowly drop into the above solution at 0°C, and stir for 30 minutes to obtain a mixed solution. Then place the mixed solution in a dropping funnel, slowly drop into the pre-prepared ethylene glycol sulfate solution (concentrated sulfuric acid (29.4 g, 0.3 mol) + ethylene glycol (150 mL)) at 0°C, and stir for 30 minutes. After the reaction is completed, add 200 mL of dichloromethane and 600 mL of water in turn, stir well, and separate the liquids. The aqueous phase is extracted once more with dichloromethane (100 mL). The organic phases were combined, washed once with saturated NaHCO3, dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-3-(1,3-dioxolan-2-yl)-propionic acid methyl ester compound D1b (10.0 g, yield 42%).
[0162] Structure identification: MS (ESI+) 239.4;
[0163] 1 H NMR (400MHz, CDCl3), δ3.19 (d, J = 5.2Hz, 2H), 3.85 (s, 3H), 3.90 (m, 2H), 4.05 (m, 2H), 5.21 (t ,5.2Hz,1H),6.52(q,J=1.6Hz,1H),6.79(d,3.2Hz,1H),7.56(s,1H),7.58(d,J=1.6Hz,1H).
[0164] (2) Compound D1b (23.8 g, 0.1 mol) was dissolved in methanol (24 mL), and phosphoric acid (85 wt%, 92.2 g, 0.8 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 24 h, and 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid methyl ester compound E1 (15.0 g, 85%);
[0165] Subsequently, compound E1 (17.6 g, 0.1 mol) was dissolved in ethanol, and sodium hydroxide (8 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0166] Application Example 4
[0167] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0168]
[0169] (1) Compound C2 (23.9 g, 0.1 mol) was dissolved in methanol (8 mL), placed in a dropping funnel, and slowly added dropwise to a mixture of lithium hydroxide (4.3 g, 0.18 mol) and methanol (45 mL) at 0°C, and stirred for 35 minutes to obtain a mixed solution; the mixed solution was placed in a dropping funnel, and slowly added dropwise to a pre-prepared sulfuric acid methanol solution (concentrated sulfuric acid (24.5 g, 0.25 mol) + methanol (145 mL)) at 0°C, and stirred for 28 minutes. After the reaction was completed, 200 mL of dichloromethane and 400 mL of water were added in sequence, stirred thoroughly, and separated. The aqueous phase was extracted once with dichloromethane (100 mL). The organic phases were combined, washed once with saturated NaHCO3, dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-4,4-dimethoxybutyric acid ethyl ester compound D2 (11.4 g, yield 45%).
[0170] Structure identification: MS (ESI+): 255.2;
[0171] 1 H NMR(400MHz, CDCl3), δ1.37(t,J=7.2Hz,3H),3.15(d,J=6.0Hz,2H),3.39(s,6H),4.30(d,J=7.2Hz,2H), 4.67 (t, J = 6.0 Hz, 1H), 6.52 (q, J = 1.6 Hz, 1H), 6.76 (d, J = 3.2 Hz, 1H), 7.52 (s, 1H), 7.57 (d, J = 1.6 Hz, 1H).
[0172] (2) Compound D2 (25.5 g, 0.1 mol) was dissolved in ethanol (24 mL), sulfuric acid (78.4 g, 0.8 mol) was added dropwise, and the mixture was stirred at room temperature for 22 h. 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid ethyl ester compound E2 (15.6 g, 82%).
[0173] Structure identification: MS (ESI+) 191.1.
[0174] 1H NMR (400MHz, CDCl3), δ1.47 (t, 3H), 4.45 (q, J=7.2Hz, 2H), 6.86 (dd, J1=2.0Hz, J2=1.0Hz, 1H), 7.68 (d, J=8.0Hz, 1H), 7.80 (d, J=2.0Hz, 1H), 8.00 (dd, J1=8.0Hz, J2=1.2Hz, 1H), 8.26 (s, 1H).
[0175] Subsequently, compound E2 (19.0 g, 0.1 mol) was dissolved in ethanol, and potassium hydroxide (11.2 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0176] Application Example 5:
[0177] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0178]
[0179] (1) Compound C2 (23.9 g, 0.1 mol) was dissolved in ethanol (20 mL), placed in a dropping funnel, and slowly added dropwise to a mixture of sodium ethoxide (13.6 g, 0.2 mol) and ethanol (50 mL) at 0°C, and stirred for 30 minutes to obtain a mixed solution. The mixed solution was then placed in a dropping funnel, and slowly added dropwise to a pre-prepared sulfuric acid ethanol solution (concentrated sulfuric acid (29.4 g, 0.3 mol) + ethanol (150 mL)) at 0°C, and stirred for 30 minutes. After the reaction was completed, 200 mL of dichloromethane and 400 mL of water were added in sequence, stirred thoroughly, and separated. The aqueous phase was extracted once with dichloromethane (100 mL). The organic phases were combined, washed once with saturated NaHCO3, dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-4,4-diethoxybutyric acid ethyl ester compound D2a (11.9 g, yield 42%).
[0180] Structure identification: MS (ESI+) 283.2;
[0181] 1H NMR(400MHz, CDCl3), δ1.19(t,J=7.2Hz,6H),1.38(t,J=7.2Hz,3H),3.15(d,J=5.6Hz,2H),3.54(m,2H),3.73(m,2H),4.30 (q,J=7.2Hz,2H),4.76(t,J=5.6Hz,3H),6.52(q,J=1.6Hz,1H),6.81(d,J=3.2Hz,1H),7.52(s,1H),7.56(d,J=1.6Hz,1H).
[0182] (2) Compound D2a (28.2 g, 0.1 mol) was dissolved in ethanol (30 mL), and phosphoric acid (85 wt%, 92.2 g, 0.8 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 24 h, and 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid ethyl ester compound E2 (15.2 g, 80%);
[0183] Subsequently, compound E2 (19 g, 0.1 mol) was dissolved in methanol, and sodium hydroxide (8 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0184] Application Example 6:
[0185] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0186]
[0187] (1) Add ethylene glycol (80 mL), add sodium hydride (8 g, 0.2 mol, 60% mineral oil dispersion) in batches under an ice-water bath, control the temperature at 0-10°C, and add it over 30 minutes. Compound C2 (23.9 g, 0.1 mol) is dissolved in ethylene glycol (20 mL), placed in a dropping funnel, slowly added to the above solution at 0°C, and stirred for 30 minutes to obtain a mixed solution. Then, the mixed solution is placed in a dropping funnel, slowly added to the pre-prepared ethylene glycol sulfate solution (concentrated sulfuric acid (29.4 g, 0.3 mol) + ethylene glycol (150 mL)) at 0°C, and stirred for 30 minutes. After the reaction is completed, add 200 mL of dichloromethane and 200 mL of water in turn, stir well, and separate the liquids. The aqueous phase is extracted once more with dichloromethane (100 mL). The organic phases were combined, washed once with saturated NaHCO 3 , dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-3-(1,3-dioxolan-2-yl)-propionic acid ethyl ester compound D2b (9.1 g, yield 36%).
[0188] Structure identification: MS (ESI+) 253.2;
[0189] 1 H NMR (400MHz, CDCl3), δ1.37 (t, J = 7.2Hz, 3H), 3.19 (d, J = 5.2Hz, 2H), 3.88 (m, 2H), 4.05 (m, 2H), 4.31 (q, J = 7. 2Hz, 2H), 5.22 (t, 5.2Hz, 1H), 6.52 (q, J = 1.6Hz, 1H), 6.76 (d, 3.6Hz, 1H), 7.55 (s, 1H), 7.57 (d, J = 1.2Hz, 1H).
[0190] (2) Compound D2b (25.3 g, 0.1 mol) was dissolved in ethanol (24 mL), and phosphoric acid (85 wt%, 92.2 g, 0.8 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 22 h, and 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid ethyl ester compound E2 (15.6 g, 82%);
[0191] Subsequently, compound E2 (19.0 g, 0.1 mol) was dissolved in ethanol, and potassium hydroxide (11.2 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0192] Application Example 7
[0193] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0194]
[0195] (1) Compound C3 (25.3 g, 0.1 mol) was dissolved in methanol (50 mL), placed in a dropping funnel, and slowly added dropwise to a mixture of sodium methoxide (11.9 g, 0.22 mol) and methanol (55 mL) at 0°C, and stirred for 28 minutes to obtain a mixed solution; the mixed solution was placed in a dropping funnel, and slowly added dropwise to a pre-prepared sulfuric acid methanol solution (concentrated sulfuric acid (34.3 g, 0.35 mol) + methanol (155 mL)) at 0°C, and stirred for 35 minutes. After the reaction was completed, 300 mL of dichloromethane and 800 mL of water were added in sequence, stirred thoroughly, and separated. The aqueous phase was extracted once with dichloromethane (200 mL). The organic phases were combined, washed once with saturated NaHCO3, dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-4,4-dimethoxybutyric acid isopropyl ester compound D3 (13.1 g, yield 49%).
[0196] Structure identification: MS (ESI+): 269.2;
[0197] 1 H NMR (400MHz, CDCl3), δ1.35 (d, J = 6.0Hz, 6H), 3.15 (d, J = 5.6Hz, 2H), 3.39 (s, 6H), 4.66 (t, J = 5.6Hz, 1H), 5. 16(septet,J=6.0Hz,1H),6.52(q,J=1.6Hz,1H),6.76(d,J=3.2Hz,1H),7.49(s,1H),7.57(d,J=1.6Hz,1H).
[0198] (2) Compound D3 (26.8 g, 0.1 mol) was dissolved in isopropanol (24 mL), and phosphoric acid (85 wt%, 92.2 g, 0.8 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 26 h, and 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid isopropyl ester compound E3 (16.3 g, yield 80%);
[0199] Structure identification: MS (ESI+): 205.1;
[0200] 1H NMR (400MHz, CDCl3), δ1.44 (d, J=6.4Hz, 6H), 5.08-5.15 (m, 1H),, 6.86 (dd, J1=2.0Hz, J2=0.8Hz, 1 H), 7.67 (d, J = 8.0Hz, 1H), 7.80 (d, J = 2.0Hz, 1H), 8.00 (dd, J1 = 8.0Hz, J2 = 1.2Hz, 1H), 8.25 (s, 1H).
[0201] Subsequently, compound E3 (20.4 g, 0.1 mol) was dissolved in ethanol, and potassium hydroxide (11.2 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0202] Application Example 8
[0203] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0204]
[0205] (1) Compound C3 (25.3 g, 0.1 mol) was dissolved in ethanol (30 mL), placed in a dropping funnel, and slowly added dropwise to a mixture of sodium ethoxide (15.0 g, 0.22 mol) and ethanol (60 mL) at 0°C, and stirred for 35 minutes to obtain a mixed solution; the mixed solution was placed in a dropping funnel, and slowly added dropwise to a pre-prepared sulfuric acid ethanol solution (concentrated sulfuric acid (34.3 g, 0.35 mol) + ethanol (155 mL)) at 0°C, and stirred for 35 minutes. After the reaction was completed, 300 mL of dichloromethane and 800 mL of water were added in sequence, stirred thoroughly, and separated. The aqueous phase was extracted once with dichloromethane (200 mL). The organic phases were combined, washed once with saturated NaHCO3, dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-4,4-diethoxybutyric acid isopropyl ester compound D3a (13.6 g, yield 46%).
[0206] Structure identification: MS (ESI+): 297.2;
[0207] 1H NMR (400MHz, CDCl3), δ1.17(t,J=7.2Hz,6H),1.33(d,J=6.4Hz,6H),3.13(d,J=6.0Hz,2H),3.53(m,2H),3.73(m,2H ), 4.74 (t, 6.0Hz, 1H), 5.14 (m, 1H), 6.50 (q, J = 1.6Hz, 1H), 6.78 (d, 3.2Hz, 1H), 7.48 (s, 1H), 7.54 (d, J = 1.2Hz, 1H).
[0208] (2) Compound D3a (29.6 g, 0.1 mol) was dissolved in isopropanol (24 mL), and phosphoric acid (85 wt%, 92.2 g, 0.8 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 26 h, and 240 mL of water and 120 mL of ethyl acetate were added, and the mixture was stirred to separate the liquids. The aqueous phase was extracted once with ethyl acetate (100 mL). The organic phases were combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid isopropyl ester compound E3 (15.9 g, yield 78%);
[0209] Subsequently, compound E3 (20.4 g, 0.1 mol) was dissolved in ethanol, and potassium hydroxide (11.2 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0210] Application Example 9
[0211] This application example provides a Liffest intermediate benzofuran-6-carboxylic acid, and the preparation method of the Liffest intermediate benzofuran-6-carboxylic acid comprises the following steps:
[0212]
[0213] (1) Add ethylene glycol (80 mL), add sodium hydride (8 g, 0.2 mol, 60% dispersed mineral oil) in batches under an ice-water bath, control the temperature at 0-10°C, and add it over 30 minutes. Compound C3 (25.3 g, 0.1 mol) is dissolved in ethylene glycol (50 mL), placed in a dropping funnel, slowly added to the above solution at 0°C, and stirred for 30 minutes to obtain a mixed solution. Then, the mixed solution is placed in a dropping funnel, slowly added to the pre-prepared ethylene glycol sulfate solution (concentrated sulfuric acid (29.4 g, 0.3 mol) + ethylene glycol (150 mL)) at 0°C, and stirred for 30 minutes. After the reaction is completed, add 300 mL of dichloromethane and 600 mL of water in turn, stir well, and separate the liquids. The aqueous phase is extracted once with dichloromethane (200 mL). The organic phases were combined, washed once with saturated NaHCO 3 , dried, spin-dried, and passed through a column to obtain 2-(furan-2-ylmethylene)-3-(1,3-dioxolan-2-yl)-propionic acid isopropyl ester compound D3b (9.3 g, yield 35%).
[0214] Structure identification: MS (ESI+): 267.2;
[0215] 1 H NMR(400MHz, CDCl3), δ1.35(d,J=6.4Hz,6H),3.18(d,J=5.6Hz,2H),3.89(m,2H),4.05(m,2H),5.17(m,1H ), 5.23 (t, J = 5.2Hz, 1H), 6.52 (q, J = 1.6Hz, 1H), 6.76 (d, J = 3.2Hz, 1H), 7.53 (s, 1H), 7.57 (d, J = 1.2Hz, 1H).
[0216] (2) Dissolve 2-(furan-2-ylmethylene)-3-(1,3-dioxolan-2-yl)-propionic acid isopropyl ester compound D3b (26.6 g, 0.1 mol) in isopropanol (30 mL), add phosphoric acid (85 wt%, 92.2 g, 0.8 mol) dropwise, stir at room temperature for 26 h after the addition is complete, add 240 mL of water and 120 mL of ethyl acetate, stir and separate. The aqueous phase is extracted once with ethyl acetate (100 mL). The organic phases are combined, washed once with water (100 mL) and saturated sodium bicarbonate (200 mL), dried over anhydrous sodium sulfate, concentrated, and passed through a column to obtain benzofuran-6-carboxylic acid isopropyl ester compound E3 (15.7 g, yield 77%);
[0217] Subsequently, compound E3 (20.4 g, 0.1 mol) was dissolved in ethanol, and potassium hydroxide (11.2 g, 0.2 mol) was added for hydrolysis to obtain benzofuran-6-carboxylic acid, an intermediate for preparing dry eye disease drugs.
[0218] Test Example 1
[0219] Yield test
[0220] The calculation results of the reaction yield of each step in Examples 1-17 are shown in Table 1 below:
[0221] Table 1
[0222]
[0223]
[0224] By comparing Example 1 with Examples 4-10, it can be seen that in step (1), the type of catalyst, reaction temperature, amount of catalyst, type of solvent, and molar amount of methyl acrylate will all affect the yield of the reaction. By comparing Examples 11-17, it can be seen that in step (3), the reaction temperature, type of solvent, molar amount of nitromethane, and molar amount of base will all affect the yield of the reaction.
[0225] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate a 2-(furan-2-ylmethylene)-4-nitrobutyrate compound and its preparation method and application, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A 2-(furan-2-ylmethylene)-4-nitrobutyrate compound, characterized in that The 2-(furan-2-ylmethylene)-4-nitrobutyrate compound has a structure as shown in the following formula I: ; Wherein, R1 is selected from C1-C6 straight chain alkyl or C1-C6 branched chain alkyl.
2. A method for preparing the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound according to claim 1, characterized in that: The preparation method comprises the following steps: (1) The compound represented by formula II is reacted with furfural in the presence of a catalyst to generate a compound represented by formula III. The reaction formula is as follows: ; (2) The compound represented by formula III is reacted with Boc anhydride in the presence of a catalyst to generate a compound represented by formula IV. The reaction formula is as follows: ; (3) reacting the compound represented by formula IV with nitromethane in the presence of a base to generate the compound represented by formula I. The reaction formula is as follows: ; Wherein, R1 in the structural formula of each step above is selected from C1-C6 straight chain alkyl or C1-C6 branched chain alkyl; In step (1), the catalyst is a tertiary amine and / or a trialkyl phosphine; In step (2), the catalyst is DMAP or any one of the compounds shown in the following formula VI: ; Among them, R d Any one selected from hydrogen, substituted or unsubstituted C1-C6 alkyl, and m is selected from an integer between 1-5.
3. The preparation method according to claim 2, characterized in that: In step (1), the molar ratio of the compound represented by formula II to furfural is 1-4:
1.
4. The preparation method according to claim 2, characterized in that: In step (1), the molar ratio of the catalyst to furfural is 0.5-1.8:
1.
5. The preparation method according to claim 2, characterized in that: The tertiary amine is DABCO, a quinoline ring or any one or a combination of at least two of the structures shown in the following formula V: ; Among them, R a , R b Each is independently selected from any one of hydrogen, substituted or unsubstituted C1-C6 alkyl; R c is selected from hydrogen; n is selected from an integer between 1-5.
6. The preparation method according to claim 2, characterized in that: The trialkylphosphine includes any one of triethylphosphine, tributylphosphine, tricyclohexylphosphine or triphenylphosphine.
7. The preparation method according to claim 2, characterized in that: In step (1), the reaction is carried out in the presence of a solvent, and the solvent is an aprotic solvent.
8. The preparation method according to claim 7, characterized in that: The aprotic solvent is any one of dichloromethane, chloroform, methyl tert-butyl ether, 1,2-dichloroethane, ethyl acetate, toluene, petroleum ether, n-hexane, n-heptane, acetonitrile, ethylene glycol dimethyl ether, N,N-dimethylformamide or dimethyl sulfoxide, or a combination of at least two thereof.
9. The preparation method according to claim 2, characterized in that: In step (1), the reaction temperature is 10-30°C and the reaction time is 40-60 h.
10. The preparation method according to claim 2, characterized in that: In step (2), the molar ratio of the compound represented by formula III to Boc anhydride is 0.8-1.2:
1.
11. The preparation method according to claim 2, characterized in that: In step (2), the molar ratio of the compound represented by formula III to the catalyst is 8-20:
1.
12. The preparation method according to claim 2, characterized in that: In step (2), the reaction is carried out in the presence of a solvent, and the solvent is an aprotic solvent.
13. The preparation method according to claim 12, characterized in that: The aprotic solvent is any one of dichloromethane, chloroform, methyl tert-butyl ether, 1,2-dichloroethane, ethyl acetate, toluene, petroleum ether, n-hexane, n-heptane, acetonitrile, ethylene glycol dimethyl ether, N,N-dimethylformamide or dimethyl sulfoxide, or a combination of at least two thereof.
14. The preparation method according to claim 2, characterized in that: In step (2), the reaction temperature is 0-30°C and the reaction time is 6-15 h.
15. The preparation method according to claim 2, characterized in that: In step (3), the molar ratio of the compound represented by formula IV to nitromethane is 1:4-6.
16. The preparation method according to claim 2, characterized in that: In step (3), the molar ratio of the compound represented by formula IV to the base is 8-12:
1.
17. The preparation method according to claim 2, characterized in that: In step (3), the base is any one of cesium carbonate, sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydroxide, lithium hydroxide or potassium hydroxide, or a combination of at least two thereof.
18. The preparation method according to claim 2, characterized in that: In step (3), the reaction is carried out in the presence of a solvent, and the solvent is a non-electrophilic solvent.
19. The preparation method according to claim 18, characterized in that: The non-electrophilic solvent is any one of 1,4-dioxane, dichloromethane, chloroform, methyl tert-butyl ether, 1,2-dichloroethane, toluene, petroleum ether, n-hexane, n-heptane or ethylene glycol dimethyl ether, or a combination of at least two thereof.
20. The preparation method according to claim 2, characterized in that: In step (3), the reaction temperature is 40-60°C and the reaction time is 6-15 h.
21. Use of the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound according to claim 1 in the preparation of Lifest, a drug for treating dry eye disease.
22. Use of the 2-(furan-2-ylmethylene)-4-nitrobutyrate compound according to claim 1 in the preparation of benzofuran-6-carboxylic acid, an intermediate of Lipfest, a drug for treating dry eye disease.
23. The use according to claim 22, characterized in that The 2-(furan-2-ylmethylene)-4-nitrobutyrate compound is first prepared to obtain a 2-(furan-2-ylmethylene)-4,4-dialkoxybutyrate compound, and then to obtain a benzofuran-6-carboxylic acid.
24. The use according to claim 23, characterized in that The structure of the 2-(furan-2-ylmethylene)-4,4-dialkoxybutyrate compound is shown in formula a-1: ; In the formula, R1 has the same definition as in claim 1, and R2 is selected from a C1-C6 straight chain alkyl group or a C1-C6 branched chain alkyl group.
25. The use according to claim 22, characterized in that The preparation method of the benzofuran-6-carboxylic acid is specifically as follows: The compound represented by formula I and a base are reacted in an alcohol solvent to obtain a mixture, and then the mixture and an acid are reacted in an alcohol solvent to obtain the 2-(furan-2-ylmethylene)-4,4-dialkoxybutyrate compound; ; Then, the 2-(furan-2-ylmethylene)-4,4-dialkoxybutyrate compound is reacted in the presence of an acid catalyst to generate a compound represented by formula a-2; ; The compound represented by formula a-2 is hydrolyzed under alkaline conditions to obtain benzofuran-6-carboxylic acid; 。
Citation Information
Patent Citations
LFA-1 inhibitor and polymorph thereof
WO2014018748A1
LFA-1 inhibitor and polymorph thereof
CN104797574A
Preparation method of benzofuran derivative
CN110684000A
Crystalline Pharmaceutical and Methods of Preparation and Use Thereof
US20110092707A1
